Key Insights

Highlights

Success Rate

93% trial completion (above average)

Published Results

14 trials with published results (35%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

5.0%

2 terminated out of 40 trials

Success Rate

92.6%

+6.1% vs benchmark

Late-Stage Pipeline

35%

14 trials in Phase 3/4

Results Transparency

56%

14 of 25 completed with results

Key Signals

14 with results93% success

Data Visualizations

Phase Distribution

29Total
Not Applicable (5)
P 1 (4)
P 2 (6)
P 3 (13)
P 4 (1)

Trial Status

Completed25
Unknown4
Recruiting3
Active Not Recruiting3
Terminated2
Not Yet Recruiting2

Trial Success Rate

92.6%

Benchmark: 86.5%

Based on 25 completed trials

Clinical Trials (40)

Showing 20 of 20 trials
NCT07250737Unknown

Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping

NCT04208529Phase 3Enrolling By Invitation

A Long-term Follow-up Study in Participants Who Received CTX001

NCT05477563Phase 3Recruiting

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

NCT07469657Not Yet Recruiting

Health Economic Evaluation of Non-Invasive Prenatal Exclusion Diagnosis

NCT03179631Phase 3Completed

Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy

NCT05356195Phase 3Active Not Recruiting

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

NCT07408583Phase 1Not Yet Recruiting

Prenatal Transplantation for Fetuses With Fanconi Anemia

NCT06917690Phase 3Recruiting

A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa

NCT03655678Phase 2Completed

A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

NCT05126758Phase 3Active Not Recruiting

A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

NCT05479981Phase 2Completed

Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients

NCT03563066Phase 2Completed

Effect of Benralizumab in Atopic Dermatitis

NCT03718234Phase 1Completed

Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia

NCT03406780Phase 2Completed

A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

NCT06337864Not ApplicableRecruiting

Effect of Large Neutral Amino Acids in Adults With Classical Phenylketonuria

NCT05290701Active Not Recruiting

Evaluating Prenatal Exome Sequencing Study

NCT02921321Completed

Pilot Study of Cardiac MR in Patients With Muscular Dystrophy

NCT05657860Phase 4Completed

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

NCT03734588Phase 1Completed

Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors

NCT03738098Not ApplicableCompletedPrimary

NYCKidSeq: Incorporating Genomics Into Clinical Care of Diverse NYC Children

Scroll to load more

Research Network

Activity Timeline